MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtha.2024.10.034

Медицинская библиотека · Journal of thrombosis and haemostasis : JTH · 2024

Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study.

Giannotta Juri Alessandro, Artoni Andrea, Mancini Ilaria, Agosti Pasquale, Carpenedo Monica, Truma Addolorata, Miri Syna, Ferrari Barbara, De Leo Pasqualina, Salutari Prassede, Mancini Giorgia, Molteni Alfredo, Rinaldi Ermina, Bocchia Monica, Napolitano Mariasanta, Prezioso Lucia, Cuccaro Annarosa, Scarpa Elisabetta, Condorelli Annalisa, Grimaldi Daniele, Massaia Massimo, Peyvandi Flora

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) patients are not responsive to standard rituximab in approximately 10% to 15% of cases, and oral immunosuppressants showed controversial results with significant toxicity. Targeting plasma cells with bortezomib appears promising, but the available evidence is scarce and stems only from isolated reports in the precaplacizumab era.

OBJECTIVES

To evaluate the safety and efficacy of bortezomib in rituximab-refractory iTTP patients.

METHODS

We conducted a retrospective observational multicenter study among 13 Italian iTTP treating centers, collecting data from May 2017 to May 2023 (caplacizumab was licensed in Italy in January 2020).

RESULTS

Bortezomib was effective in 10/17 patients (59%). Eleven were treated in the acute phase (9/11 responders, 82%, allowing discontinuation of caplacizumab in 5/6 treated patients), and 7 during clinical remission (2/7 responders, 28%). Responses occurred at a median time of 30 days, but 3 patients responded after 4 months. The median duration of response was 22 months (IQR, 10-38), still ongoing in 6 patients at the time of data cutoff. Responders had fewer previous acute iTTP episodes than nonresponders (median [IQR], 1 [1,2] vs 5.5 [2-7]; P = .03). Eight subjects (47%) reported toxicities, mostly in those treated with ≥2 cycles.

CONCLUSION

Durable responses to bortezomib were registered in about 60% of multirefractory iTTP patients with mild to moderate toxicities. The occurrence of late responses (ie, after 30 days) suggests a "watchful waiting" approach after bortezomib treatment.

Для цитирования: Giannotta Juri Alessandro, Artoni Andrea, Mancini Ilaria, Agosti Pasquale, Carpenedo Monica, Truma Addolorata, Miri Syna, Ferrari Barbara, De Leo Pasqualina, Salutari Prassede, Mancini Giorgia, Molteni Alfredo, Rinaldi Ermina, Bocchia Monica, Napolitano Mariasanta, Prezioso Lucia, Cuccaro Annarosa, Scarpa Elisabetta, Condorelli Annalisa, Grimaldi Daniele, Massaia Massimo, Peyvandi Flora. Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study.. Journal of thrombosis and haemostasis : JTH. 2024. DOI: 10.1016/j.jtha.2024.10.034.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.